Leonteq Securities AG Has $1.08 Million Stock Holdings in Elevance Health, Inc. $ELV

Leonteq Securities AG lifted its position in Elevance Health, Inc. (NYSE:ELV) by 99.6% during the 1st quarter, Holdings Channel reports. The firm owned 3,700 shares of the company’s stock after buying an additional 1,846 shares during the quarter. Leonteq Securities AG’s holdings in Elevance Health were worth $1,083,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ELV. Kemnay Advisory Services Inc. bought a new stake in Elevance Health during the fourth quarter worth about $31,000. J.Safra Asset Management Corp bought a new position in shares of Elevance Health in the fourth quarter valued at approximately $32,000. ORG Partners LLC raised its stake in shares of Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in shares of Elevance Health in the 4th quarter worth approximately $38,000. Finally, Dorato Capital Management acquired a new position in shares of Elevance Health in the 4th quarter worth approximately $41,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Performance

Shares of Elevance Health stock opened at $416.97 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The firm has a market cap of $90.55 billion, a P/E ratio of 17.74, a P/E/G ratio of 2.37 and a beta of 0.67. The firm has a 50 day simple moving average of $391.29 and a 200 day simple moving average of $351.14. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $427.19.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Sell-side analysts predict that Elevance Health, Inc. will post 26.86 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were given a dividend of $1.72 per share. The ex-dividend date was Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. Elevance Health’s payout ratio is presently 29.26%.

Insider Activity

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.34% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ELV shares. Wall Street Zen raised Elevance Health from a “hold” rating to a “buy” rating in a report on Saturday. Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $363.00 to $498.00 in a research note on Wednesday, May 20th. Sanford C. Bernstein increased their target price on Elevance Health from $424.00 to $482.00 and gave the stock an “outperform” rating in a report on Thursday. Bank of America raised their target price on Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a research note on Thursday, June 4th. Finally, Evercore reaffirmed a “hold” rating on shares of Elevance Health in a report on Tuesday, May 19th. Fourteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $419.16.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.